Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | FGF1 | P05230 | 3/20 | 0.43 |
| ▸ | FGF2 | P09038 | 2/20 | 0.43 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | BDNF | P23560 | 2/20 | 0.34 |
| ▸ | PTN | P21246 | 1/20 | 0.34 |
| ▸ | MDK | P21741 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534894 | 0.89 | F10 (0.43) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL29535345 | 0.86 | LGALS3 (0.38) | F10SERPINC1F2LGALS3 | |
| SCHEMBL1009127 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL20987120 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL7209912 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL16728926 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL13286928 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL21067663 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL7209918 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL16729027 | 0.83 | F10 (0.41) | F10FGF1FGF2SERPINC1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366853-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | EXTHERA MEDICAL CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| US-12090261-B2 | Method for modulating endothelial glycocalyx structure | EXTHERA MEDICAL CORPORATION (US) | 2024-09-17 | — | — | US | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |